<DOC>
	<DOCNO>NCT02525068</DOCNO>
	<brief_summary>A multicentre prospective , randomise , phase II interventional study mCRPC patient previously treat 1‐2 line chemotherapy least 12 week abiraterone safety run‐in single stage phase II expansion cohort .</brief_summary>
	<brief_title>A Study Enzalutamide Combination With AZD5363 Patients With mCRPC</brief_title>
	<detailed_description>Patients mCRPC receive enzalutamide AZD5363 ( enzalutamide placebo randomise phase II ) confirm disease progression . The trial aim identify safety tolerability enzalutamide AZD5363 identify recommended phase II dose AZD5363 ( phase I safety run-in ) . The randomised phase II estimate compare anti-tumour activity AZD5363 enzalutamide , placebo enzalutamide measure response . The single stage phase II expansion cohort estimate anti-tumour activity AZD5363 enzalutamide patient previously progress enzalutamide alone .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Written informed consent . 2 . Histological diagnosis adenocarcinoma prostate tumour tissue accessible research analyse trial ( e.g . Phosphatase Tensin Homologue ( PTEN ) test ) . Patients histological diagnosis must willing undergo biopsy prove prostate adenocarcinoma . 3 . Metastatic CastrationResistant Prostate Cancer ( mCRPC ) . 4 . Progressed 1 2 line taxane base chemotherapy . 5 . Progressed abiraterone ( pre post chemotherapy ) . Patients must receive least 12 week treatment abiraterone . 6 . Age ≥18 year . 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 02 . 8 . PSA ≥ 10ng/ml . 9 . Documented willingness use effective mean contraception participate study 12 month post last dose treatment 10 . Documented ongoing castrate serum testosterone &lt; 50 ng/dL ( &lt; 2.0 nM ) . 11 . Received prior castration orchiectomy and/or ongoing Luteinizing HormoneReleasing Hormone ( LHRH ) agonist treatment . 12 . Progression disease PSA utilize PCWG2 criterion least another following criterion ; 1 . Bone scan : disease progression define least 2 new lesion bone scan . 2 . Soft tissue disease progression define modified RECIST 1.1 . 3 . Clinical progression worsen pain need palliative radiotherapy bone metastasis . PHASE I SAFETY RUN IN EXPANSION COHORT inclusion criterion : 13 . Willing biopsy obtain tumour tissue biomarker analyse prior treatment . SINGLE STAGE PHASE II EXPANSION COHORT ONLY inclusion criterion : 14 . Prior exposure enzalutamide least 12 week require documented disease progression biochemically and/or radiologically PCWG2 RECIST 1.1 criterion . Patients receive least 12 week enzalutamide outside trial evidence disease progression ( PSA 3 rise value per PCWG2 criterion soft tissue progression per RECIST v1.1 ) . 15 . Archival tumour tissue available analysis PTEN loss central laboratory 1 . Prior treatment enzalutamide ( MDV3100 ) ( applicable phase I safety run single stage phase II expansion cohort , see inclusion criterion 14 ) . 2 . Prior treatment Phosphatidylinositide 3‐kinases ( PI3K ) , AKT , TOR kinase Mammalian target rapamycin ( mTOR ) inhibitor ( see Appendix C ) . 3 . Surgery , chemotherapy , anti‐cancer therapy within 4 week prior trial entry/randomisation study ( 6 week bicalutamide ) . Any therapy prostate cancer , Gonadotropinreleasing hormone ( GnRH ) analogue therapy , progesterone , medroxyprogesterone , progestin ( megestrol ) , 5‐alpha reductase inhibitor ( e.g. , finasteride dutasteride ) , must discontinue least 2 week first dose study drug . 4 . Participation another clinical trial concurrent treatment investigational drug within 4 week prior trial entry / randomisation . 5 . Prior limited field radiotherapy within 2 week wide field radiotherapy within 4 week trial entry / randomisation . 6 . History seizure condition may predispose seizure include , limited underlie brain injury , stroke , primary brain tumour , brain metastasis , alcoholism . 7 . History loss consciousness transient ischemic attack within previous 12 month trial entry / randomisation . 8 . Known brain leptomeningeal involvement . 9 . Use potent inhibitor inducer Cytochrome P450 isoenzymes ( CYP3A4 , CYP2C9 CYP2C19 ) ( see Appendix B ) within 2 week trial entry / randomisation ( 3 week St John 's Wort ) must avoid . 10 . Clinically significant abnormality glucose metabolism define follow : 1 . Diagnosis diabetes mellitus type I II ( irrespective management ) . 2 . Glycosylated haemoglobin ( HbA1C ) ≥8.0 % screening ( 64 mmol/mol ) ( conversion equation HbA1C [ IFCC‐HbA1C ( mmol/mol ) = [ DCCT‐HbA1C ( % ) 2.15 ] x 10.929 ) 3 . Fasting Plasma Glucose ≥ 8.9mmol/L screening . Fasting define caloric intake least 8 hour . 11 . Inadequate organ bone marrow function evidence : 1 . Haemoglobin &lt; 8.5 g/dL 2 . Absolute neutrophil count &lt; 1.0 x 109/L 3 . Platelet count &lt; 75 x 109/L 4 . Albumin ≤25 g/dL . 5 . Aspartate Transaminase ( AST ) / Serum Glutamic‐Oxaloacetic Transaminase ( SGOT ) and/or Alanine Transaminase ( ALT ) / Serum Glutamic Pyruvate Transaminase ( SGPT ) ≥ 2.5 x Upper Limit Normal ( ULN ) ( ≥ 5 x ULN liver metastasis present ) 6 . Total bilirubin ≥ 1.5 x ULN ( except patient document Gilbert 's disease ) 7 . Serum Creatinine &gt; 1.5 x ULN 12 . Inability unwillingness swallow oral medication . 13 . Malabsorption syndrome condition would interfere enteral absorption . 14 . Any following cardiac criterion ; 1 . Mean resting correct QT interval ( QTcF ) &gt; 470msec obtain 3 consecutive ECGs take within 5 minute 2 . Any clinically important abnormality rhythm , conduction , morphology rest ECG ( e.g. , complete leave bundle branch block , third degree heart block ) 3 . Any factor increase risk QTc prolongation risk arrhythmic event heart failure , hypokalaemia , congenital long QT syndrome , family history long QT syndrome unexplained sudden death 40 years‐of‐age , concomitant medication know prolong QT interval potential Torsades de Pointes 4 . Experience follow procedure condition precede six month : coronary artery bypass graft , angioplasty , vascular stent , myocardial infarction , angina pectoris , congestive heart failure New York Heart Association ( NYHA ) ≥ Grade2 5 . Uncontrolled hypotension define systolic blood pressure ( BP ) &lt; 90 mmHg and/or diastolic BP &lt; 50 mmHg 15 . Clinically significant history liver disease consistent Child‐Pugh Class B C , include viral hepatitis , current alcohol abuse , cirrhosis . 16 . Any finding give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render patient high risk treatment complication . 17 . Need chronic corticosteroid therapy &gt; 10 mg prednisolone &gt; 0.5mg dexamethasone per day equivalent dose anti‐inflammatory corticosteroid , use concomitant steroid trial please refer section 12.1 . Patients corticosteroid stop prior enter trial allow maximum 10mg prednisolone per day equivalent . In case corticosteroid discontinuation , 2‐week ( 14 day ) washout required mandatory PSA check prior start trial . If PSA decline compare value obtain prior stop corticosteroid , patient eligible study . Patients enter study confirm PSA increase . 18 . Malignancies prostate cancer within 5 year prior trial entry / randomisation , except adequately treat basal squamous cell skin cancer . 19 . Unresolved clinically significant toxicity prior therapy except alopecia Grade 1 peripheral neuropathy . 20 . Inability comply study follow‐up procedure . 21 . Patients predominately small cell neuroendocrine differentiate prostate cancer eligible .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>enzalutamide</keyword>
	<keyword>AZD5363</keyword>
	<keyword>Prostate</keyword>
</DOC>